Advances in the prevention, management and treatment of community-acquired pneumonia
Data(s) |
2010
|
---|---|
Resumo |
Despite the availability of powerful antibiotics, community-acquired pneumonia (CAP) remains one of the leading reasons for morbidity and mortality worldwide, and despite the availability of powerful antibiotics, there has been only little improvement in case fatality rates for many years. Consequently, it cannot be expected that novel antibiotics will substantially improve outcomes in CAP. Therefore, this review focuses on novel approaches that may reduce CAP-related mortality: the impact of immunomodulation by macrolides and fluoroquinolones and the prevention of CAP by pneumococcal vaccines. |
Formato |
application/pdf |
Identificador |
http://boris.unibe.ch/2325/1/5.pdf Pletz, MW; Welte, T; Ott, SR (2010). Advances in the prevention, management and treatment of community-acquired pneumonia. F1000 medicine reports, 2, p. 53. London: BioMed Central doi:10.7892/boris.2325 urn:issn:1757-5931 |
Idioma(s) |
eng |
Publicador |
BioMed Central |
Relação |
http://boris.unibe.ch/2325/ |
Direitos |
info:eu-repo/semantics/openAccess |
Fonte |
Pletz, MW; Welte, T; Ott, SR (2010). Advances in the prevention, management and treatment of community-acquired pneumonia. F1000 medicine reports, 2, p. 53. London: BioMed Central |
Tipo |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion PeerReviewed |